Ask AI
HER2 Positive GEA and BTC IDST
Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance

Released: April 24, 2026

References

Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer: assessment of prognostic value and evaluation of therapeutic potentials. Crit Rev Oncol Hematol. 2016:97:65-71.

Ayasun R, Ozer M, Sahin I. The role of HER2 status in the biliary tract cancers. Cancers (Basel). 2023;15:2628.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.

Bao X, Chen Z, Xiong J, et al. Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with trastuzumab deruxtecan (T-DXd): a case report. Medicine (Baltimore). 2025;104:e44094.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-209.

Coutzac C, Funk-Debleds P, Cattey-Javouhey A, et al. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: what is new? Bull Cancer. 2023;110:552-559.

de la Fouchardière C, Cammarota A, Svrcek M, et al. How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force. Cancer Treat Rev. 2025;134:102890.

Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca; 2025.

Elimova E, Rha SY, Shitara K, et al. Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): primary analysis from HERIZON-GEA-01. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026; January 8-10, 2026. Abstract LBA285.

Formica V, Morelli C, Fornaro L, et al. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials. ESMO Open. 2024;9:103967.

Fuchs CS, Doi T, Jang, RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013.

Gujarathi R, Peshin S, Zhang X, et al. Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel. Hepatol Commun. 2025;9:e0743.

Haaft BHT, Pedregal M, Prato J, et al. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: current advancements and future perspectives. Eur J Cancer. 2024;199:113564.

Harding JJ, Fan J, Oh DY, et al. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer. Future Oncol. 2024;20:2319-2329.

Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772-782.

Hussain MM, Qammar S, Wang JM, et al. Recent advancements in systemic therapy for biliary tract cancers: a literature review. J Gastrointest Oncol. 2025;16:2402-2429.

Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol. 2024;42:2012-2020.

Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197-2208.

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.

Joseph A, Raja S, Kamath S. et al. Esophageal adenocarcinoma: a dire need for early detection and treatment. Cleve Clin J Med. 2022;89:269-279.

Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853-1865.

Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690-701.

Lee YP, Oh SY, Kim KM, et al. Modified FOLFIRINOX as a second-line treatment for patients with gemcitabine-failed advanced biliary tract cancer: a prospective multicenter phase II study. Cancers (Basel). 2022;14:1950.

Ma C, Wang X, Jiwu Guo J, et al. Challenges and future of HER2-positive gastric cancer therapy. Front Oncol. 2023;13:1080990.

Martinez-Ciarpaglini C, Ortega M, Pérez-Buira S, et al. CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients. Virchows Arch. 2025;487:1337-1346.

Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47-58.

Metges JP, Kato K, Sun JM, et al. Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study. ESMO Open. 2025;10:105854.

Mo C, Sterpi M, Jeon H, et al. Resistance to anti-HER2 therapies in gastrointestinal malignancies. Cancers (Basel). 2024;16:2854.

Moehler M, Yoon HH, Wagner DC, et al. Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab. Mod Pathol. 2025;38:100793.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: biliary tract cancers. V1.2026. nccn.org. Accessed April 21, 2026.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. v2.2026. nccn.org. Accessed April 21, 2026.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: gastric cancer. V2.2026. nccn.org. Accessed April 21, 2026.

Nivolumab [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2025.

Oh DY, He AR, Bouattour M. et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694-704.

Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.

Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2025.

Pirrone C, Malapelle U, Pepe F, et al. Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab. Eur J Cancer. 2025;230:116035.

Pudlarz T, Turpin A, Tissera NS, et al. Young-onset biliary tract cancers: characteristics, treatment patterns, and patient outcomes. JHEP Rep. 2025;7:101550.

Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024:385:e078876.

Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:1147-1162.

Rimini M, Fornaro L, Ikeda M, et al. Durvalumab in advanced biliary tract cancer: real-world data from a large cohort of patients across multiple international centers. Liver Int. 2025;45:e70428.

Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419-2430.

Shitara K, Shoji H, Fazio N, et al. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026;Epub.

Shitara K, Van Cutsem E, Gümüş M, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393:336-348.

Shitara K, Xu RH, Ajani JA, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27:1058-1068.

Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024;25:439-454.

Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759-771.

Sungwan P, Panaampon J, Sumankan R, et al. Emerging HER2 targeting immunotherapy for cholangiocarcinoma. Oncol Res. 2025;33:2279-2307.

Tariq NU, McNamara MG, Valle JW, et al. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019;11:2623-2642.

Tesini G, Ibrahim H, Rimassa L, et al. Evolving precision: updates in targeted therapy for cholangiocarcinoma. Hepatology. 2025;[Epub ahead of print].

Trastuzumab [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2024.

Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2025.

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-1281.

Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476-84.

Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744-756.

Van Cutsem E. Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study. Future Oncol. 2025;21:3691-3700.

Wonglhow J, Wong HL, Michael M. Effectiveness of chemotherapy plus immunotherapy and molecular alterations in advanced biliary tract cancer: real-world evidence from a single-center Australian cohort. Cancer Control. 2025;32:10732748251397095.

Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24:483-495.

Yamada D, Kobayashi S, Doki Y, et al. Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies. Int J Clin Oncol. 2025;30:1069-1079.

Zanidatamab [prescribing information]. Palo Alto, CA: Jazz; 2025.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with HER2-positive advanced GEA and BTC. The information provided is based on guideline recommendations and expert guidance of Richard Kim, MD; Geoffrey Ku, MD; Amit Mahipal, MD, MPH; Shubham Pant, MD; and Rachna T. Shroff, MD, MS, FASCO.

The material published by Decera Clinical Education reflects the views of the reviewers or authors of the material, not those of Decera Clinical Education, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content